Myocarditis following COVID-19 mRNA vaccination.
Myocarditis following COVID-19 mRNA vaccination.
复制标题
DOI：
10.1016/j.vaccine.2021.05.087
复制
发表时间：
2021-06-29
期刊：
影响因子：
5.5
通讯作者：
Berar Yanay N
中科院分区：
文献类型：
--
作者：
Abu Mouch S;Roguin A;Hellou E;Ishai A;Shoshan U;Mahamid L;Zoabi M;Aisman M;Goldschmid N;Berar Yanay N
BNT162b2疫苗的临床试验显示出有效性和安全性。我们报告6例心肌炎，在接种BNT162b2疫苗后不久发生。患者在被送往急诊科时被发现有胸痛/不适的症状。在所有研究患者中，我们排除了既往和现在的新冠肺炎。对心肌炎的常见病因进行常规的临床和实验室检查。实验室检测还包括肌钙蛋白和C反应蛋白水平。心肌炎的诊断是在心脏MRI后确定的。5名患者在第二次接种疫苗后出现，1名患者在第一剂疫苗接种后出现。所有患者均为男性，年龄中位数为23岁。所有患者都被诊断为心肌炎，没有证据表明新冠肺炎感染。实验室检测排除了伴随感染；自身免疫性疾病被认为是不可能的。所有患者对BNT162b2疫苗均有反应。所有6名患者的临床病程都很轻微。我们关于接种BNT162b2疫苗后的心肌炎的报道可能被认为是免疫后的不良反应。我们认为，我们的信息应谨慎解读，并有必要进行进一步的监控。
Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination. Patients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. In all study patients, we excluded past and current COVID-19. Routine clinical and laboratory investigations for common etiologies of myocarditis were performed. Laboratory tests also included troponin and C-reactive protein levels. The diagnosis of myocarditis was established after cardiac MRI. Five patients presented after the second and one after the first dose of the vaccine. All patients were males with a median age of 23 years. Myocarditis was diagnosed in all patients, there was no evidence of COVID-19 infection. Laboratory assays excluded concomitant infection; autoimmune disorder was considered unlikely. All patients responded to the BNT162b2 vaccine. The clinical course was mild in all six patients. Our report of myocarditis after BNT162b2 vaccination may be possibly considered as an adverse reaction following immunization. We believe our information should be interpreted with caution and further surveillance is warranted.
登录
查看更多内容
DOI：
10.1038/nrd.2017.243
发表时间：
2018-04
期刊：
Nature reviews. Drug discovery
影响因子：
--
作者：
Pardi N;Hogan MJ;Porter FW;Weissman D
通讯作者：
Weissman D
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.5
作者：
Kuntz, Jennifer;Crane, Bradley;Naleway, Allison L.
通讯作者：
Naleway, Allison L.
影响因子：
39.3
作者：
Caforio, Alida L. P.;Adler, Yehuda;Linhart, Ales
通讯作者：
Linhart, Ales
免疫实践咨询委员会的临时建议，用于使用Pfizer-Biontech Covid-19-1920年12月，美国。
DOI：
10.15585/mmwr.mm6950e2
发表时间：
2020-12-18
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Oliver SE;Gargano JW;Marin M;Wallace M;Curran KG;Chamberland M;McClung N;Campos-Outcalt D;Morgan RL;Mbaeyi S;Romero JR;Talbot HK;Lee GM;Bell BP;Dooling K
通讯作者：
Dooling K